The Rasonque pancreatic cancer treatment from Revolution Medicines has received US Food and Drug Administration (FDA) approval for certain patients with metastatic disease. The once-daily oral medicine, also known as daraxonrasib, is approved for patients who have received previous treatment or cannot undergo combination chemotherapy. It targets several forms of the RAS protein, which plays a significant role in driving…
Tag: Revolution Medicines
-
Daraxonrasib Pancreatic Cancer Results: A Historic Breakthrough
Every so often, a medical advance is so significant that it gives seasoned oncologists chills. This is currently the case for Revolution Medicines and their experimental therapy, daraxonrasib. In a recent late-stage study, the drug allowed patients with advanced disease to live twice as long as those receiving standard chemotherapy. For a field where progress is often measured in mere…